Search | Page 5 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.

    ... August 22, 2012 Lenalidomide and azacitidine each have activity in ... therapy with azacitidine (75mg/m(2)/d x 5 days) and lenalidomide (10mg/d x 21 days (28-day cycle)) in patients with higher-risk ...

    Research Article last updated 10/01/2012 - 9:58am.

  2. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents

    ... 23, 2011 Lenalidomide (LEN) has been shown to yield red blood cell (RBC) ...

    Research Article last updated 04/24/2012 - 2:47pm.

  3. Combination of Azacitidine and Lenalidomide in Myelodysplastic Syndromes or acute Myeloid Leukemia-a wise Liaison?

    ... Currently, combination therapies of azacitidine with lenalidomide appear to be promising thus making them an appealing option ...

    Research Article last updated 06/20/2013 - 11:05am.

  4. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)

    ... for ESA- refractory or relapsed patients include lenalidomide , alone or in combination with ESAs; oral azacitidine ; ...

    Research Article last updated 12/09/2016 - 2:50pm.

  5. Recent developments in bone marrow transplants

    ... bone marrow transplantation. A prolonged course of lenalidomide (Revlimid, Celgene) maintenance following autologous ...

    Article last updated 11/16/2016 - 2:56pm.

  6. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol

    ... with less than 50 % response, lasting 2 years. Aza and lenalidomide (Len) have a potential synergistic effect. ViLen-01 phase IIa ...

    Research Article last updated 09/13/2016 - 2:47pm.

  7. Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience

    ... use or response to hypomethylating agents were observed. Lenalidomide therapy was seldom used in AYA, as none presented with del5q. ...

    Research Article last updated 09/19/2016 - 11:09am.

  8. Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma

    ... Purpose:  Lenalidomide has been shown to have single agent activity in indolent ... The purpose of this study is to see how well giving lenalidomide together with rituximab works in treating patients with previously ...

    Clinical Trial last updated 06/06/2016 - 10:17am.

  9. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

    ...

    Research Article last updated 02/04/2013 - 2:29pm.

  10. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure

    ... architectures specifically upon treatment with lenalidomide and other drugs. Despite initial clinical response to ...

    Research Article last updated 07/18/2016 - 11:18am.